Randomised clinical trial: a liquid multi‐strain probiotic vs. placebo in the irritable bowel syndrome – a 12 week double‐blind study

Sisson, G.; Ayis, S.; Sherwood, R. A.; Bjarnason, I.

doi:10.1111/apt.12787

Cited by 147Gastrointestinal motility and disordersProbiotics and Fermented FoodsGut microbiota and health

Randomised clinical trial: a liquid multi‐strain probiotic vs. placebo in the irritable bowel syndrome – a 12 week double‐blind study

Open access

Sisson, G., Ayis, S., Sherwood, R. A., Bjarnason, I.·2014·Alimentary Pharmacology & Therapeutics

DOI 10.1111/apt.12787

Open this paper in CoChat — free account

Abstract

Summary: Background: The importance of interactions between the host and gut microbiota in the pathogenesis of irritable bowel syndrome ( IBS ) is becoming increasingly apparent. Probiotics offer a potential new treatment for IBS , but current results are conflicting, largely as a result of poorly designed trials and nonstandardisation of outcome measures. Aim: To assess the efficacy of a liquid, multi‐strain probiotic (Symprove) in IBS . Methods: A single‐centre, randomised, double‐blind, placebo‐controlled trial of adult patients with symptomatic IBS . Patients received 12 weeks of treatment with the probiotic or placebo (1 mL/kg/day). The primary efficacy measure was the difference in change in the IBS symptom severity score ( IBS ‐ SSS ) between probiotic vs. placebo at week 12. Secondary outcome measures included change in the IBS quality of life ( IBS ‐ QOL ) score and change in the IBS ‐ SSS symptom component scores. Results: A total of 186 patients were randomised and 152 patients completed the study. The mean change in IBS ‐ SSS was −63.3 probiotic vs. −28.3 placebo. The mean difference in the IBS ‐ SSS was statistically significant [−35.0 (95% CI ; −62.03, −7.87); P = 0.01]. There was no significant improvement in the IBS ‐ QOL . No serious adverse events were reported. Conclusions: The multi‐strain probiotic was associated with a statistically significant improvement in overall symptom severity in patients with IBS , and was well tolerated. These results suggest this probiotic confers benefit in IBS and deserves further investigation (ISRCTN identifier: 77512412).

Integrity signals

Registry

Crossref · 10.1111/apt.12787

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Probiotics are beneficial in improving overall symptoms in patients with IBS, but there are contradictory reports on improvements in specific symptoms.
“Based on the international consensus and existing evidence, probiotics are beneficial in improving overall symptoms in patients with IBS [29,30,31,32,33,34,35], but there are still contradictory reports on improvements in specific symptoms [36,37,38].”
From Effectiveness and Safety of Probiotics for Patients with Constipation-Predominant Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of 10 Randomized Controlled Trials (2022) · cites this paper as [38]

The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress
FRANCIS, C. Y., MORRIS, J., & WHORWELL, P. J. (1997) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1997.142318000.x · Cited by 1,708 · cited 2× · see citing works
“This level was chosen to ensure that patients were at least symptomatic and that it would be possible to detect a ‘clinically important’ change in the IBS-SSS of ≥50 as defined by the original authors of this scale.(24) Patients with all sub-types of IBS, based on prominence of stool symptoms, were included in the stu…”
MethodResult
Lactobacillus and bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles
O’Mahony, L., McCarthy, J., Kelly, P., Hurley, G., Luo, F., Chen, K., O’Sullivan, G. C., Kiely, B., Collins, J. K., Shanahan, F., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.11.050 · Cited by 1,448 · see citing works
Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation
Pimentel, M., Lembo, A., Chey, W. D., Zakko, S., Ringel, Y., Yu, J., Mareya, S. M., Shaw, A. L., Bortey, E., & Forbes, W. P. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1004409 · Cited by 1,036 · see citing works
The Fecal Microbiota of Irritable Bowel Syndrome Patients Differs Significantly From That of Healthy Subjects
Kassinen, A., Krogius-Kurikka, L., Mäkivuokko, H., Rinttilä, T., Paulin, L., Corander, J., Malinen, E., Apajalahti, J., & Palva, A. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.005 · Cited by 1,002 · see citing works
St John's wort for depression—an overview and meta-analysis of randomised clinical trials
Linde, K., Ramı́rez, G., Mulrow, C. D., Pauls, A., Weidenhammer, W., & Melchart, D. (1996) · BMJ · doi:10.1136/bmj.313.7052.253 · Cited by 989 · see citing works
Intestinal permeability: an overview
Bjarnason, I., Macpherson, A., & Hollander, D. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90708-4 · Cited by 927 · cited 1× · see citing works
“Some patients may be taking over the counter aspirin or NSAIDs, while others may be misusing or sensitive to the intestinal effects of alcohol.(32)”
BackgroundSelf-citation
Strategy for intention to treat analysis in randomised trials with missing outcome data
White, I. R., Horton, N. J., Carpenter, J. R., statistics, R. I. M. A. S., & Pocock, S. (2011) · BMJ · doi:10.1136/bmj.d40 · Cited by 849 · see citing works
Guidelines on the irritable bowel syndrome: mechanisms and practical management
Spiller, R., Aziz, Q., Creed, F., Emmanuel, A., Houghton, L., Hungin, P., Jones, R., Kumar, D., Rubin, G., Trudgill, N., et al. (2007) · Gut · doi:10.1136/gut.2007.119446 · Cited by 818 · see citing works
Efficacy of an Encapsulated Probiotic Bifidobacterium infantis 35624 in Women with Irritable Bowel Syndrome
Whorwell, P. J., Altringer, L., Morel, J., Bond, Y., Charbonneau, D., O'Mahony, L., Kiely, B., Shanahan, F., & Quigley, E. M. M. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00734.x · Cited by 799 · see citing works
Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors
Rousseaux, C., Thuru, X., Gelot, A., Barnich, N., Neut, C., Dubuquoy, L., Dubuquoy, C., Merour, E., Geboes, K., Chamaillard, M., et al. (2007) · Nature Medicine · doi:10.1038/nm1521 · Cited by 793 · see citing works
Quality of Life in Persons with Irritable Bowel Syndrome (Development and Validation of a New Measure)
Patrick, D. L., Drossman, D. A., Frederick, I. O., Dicesare, J., & Puder, K. L. (1998) · Digestive Diseases and Sciences · doi:10.1023/a:1018831127942 · Cited by 761 · see citing works
Evidence‐based dietary management of functional gastrointestinal symptoms: The FODMAP approach
Gibson, P. R., & Shepherd, S. (2009) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2009.06149.x · Cited by 657 · see citing works
Abnormal Intestinal Permeability in Subgroups of Diarrhea-Predominant Irritable Bowel Syndromes
Dunlop, S. P., Hebden, J., Campbell, E., Naesdal, J., Olbe, L., Perkins, A. C., & Spiller, R. C. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00672.x · Cited by 476 · cited 1× · see citing works
“thermore, only two patients had increased small intestinal permeability, which is in keeping with some 33 but not all previous studies.(34) Furthermore; faecal calprotectin was raised in less than 15% of patients, again in keeping with previous results.”
Result
Non-colonic features of irritable bowel syndrome.
Whorwell, P. J., McCallum, M., Creed, F. H., & Roberts, C. T. (1986) · Gut · doi:10.1136/gut.27.1.37 · Cited by 473 · cited 1× · see citing works
“dysfunction, and anxiety and mood disorders are frequently present.(3) Taken collectively, the symptoms of IBS may impact significantly on quality of life (QOL) and result in substantial increased direct health care costs, 5 as well as indirect costs such as absenteeism from work.”
Background
Host–Bacterial Symbiosis in Health and Disease
Chow, J., Lee, S. M., Shen, Y. L., Khosravi, A., & Mazmanian, S. K. (2010) · Advances in immunology · doi:10.1016/b978-0-12-381300-8.00008-3 · Cited by 467 · see citing works
Medical costs in community subjects with irritable bowel syndrome
Talley, N. J., Gabriel, S. E., Harmsen, W. S., Zinsmeister, A. R., & Evans, R. W. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90738-6 · Cited by 460 · see citing works
Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice
Verdú, E. F., Bercik, P., Verma-Gandhu, M., Huang, X.-X., Blennerhassett, P., Jackson, W., Mao, Y., Wang, L., Rochat, F., & Collins, S. M. (2006) · Gut · doi:10.1136/gut.2005.066100 · Cited by 448 · see citing works
Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease
Tibble, J. A., Sigthorsson, G., Foster, F., Forgács, I., & Bjarnason, I. (2002) · Gastroenterology · doi:10.1053/gast.2002.34755 · Cited by 437 · cited 1× · see citing works
“Furthermore; faecal calprotectin was raised in less than 15% of patients, again in keeping with previous results.(33) The reason some patients with IBS have mild intestinal inflammation is unknown.”
ResultSelf-citation
Effect of a fermented milk containing <i>Bifidobacterium animalis</i> DN‐173 010 on the health‐related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double‐blind, controlled trial
GUYONNET, D., CHASSANY, O., DUCROTTE, P., PICARD, C., MOURET, M., MERCIER, C. ‐., & MATUCHANSKY, C. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03362.x · Cited by 365 · see citing works
A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6‐month intervention
KAJANDER, K., HATAKKA, K., POUSSA, T., FÄRKKILÄ, M., & KORPELA, R. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02579.x · Cited by 361 · see citing works
A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome
Hoveyda, N., Heneghan, C., Mahtani, K. R., Perera, R., Roberts, N., & Glasziou, P. (2009) · BMC Gastroenterology · doi:10.1186/1471-230x-9-15 · Cited by 297 · see citing works
Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease.
Takeuchi, K., Smale, S., Premchand, P., Maiden, L., Sherwood, R., Thjódleifsson, B., Björnsson, E., & Bjarnason, I. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(05)00980-8 · Cited by 293 · see citing works
Self-citation
VSL#3 improves symptoms in children with irritable bowel syndrome: a multicenter, randomized, placebo-controlled, double-blind, crossover study
Guandalini, S., Magazzù, G., Chiaro, A., La Balestra, V., Di Nardo, G., Gopalan, S., Sibal, A., Romano, C., Canani, R. B., Lionetti, P., et al. (2010) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0b013e3181ca4d95 · Cited by 273 · see citing works
A Molecular Analysis of Fecal and Mucosal Bacterial Communities in Irritable Bowel Syndrome
Codling, C., O’Mahony, L., Shanahan, F., Quigley, E. M. M., & Marchesi, J. R. (2010) · Digestive Diseases and Sciences · doi:10.1007/s10620-009-0934-x · Cited by 243 · see citing works
Klaus Linde, Gilbert Ramirez, Cynthia D. Mulrow, Andrej Pauls, Wolfgang Weidenhammer, and Dieter Melchart. (1996). St. John's wort for depression—An overview and meta-analysis of randomized clinical trials. British Medical Journal, 313, 3 August 1996, 253-8
Hazzard, M. (1997) · Complementary health practice review · doi:10.1177/153321019700300312 · Cited by 224 · see citing works
Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice - an evidence-based international guide
Hungin, A. P. S., Mulligan, C., Pot, B., Whorwell, P., Agréus, L., Fracasso, P., Lionis, C., Mendive, J., Philippart de Foy, J.-M., Rubin, G., et al. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12460 · Cited by 212 · cited 17× · see citing works
“A further indication of severity is the fact that these patients had failed most other conventional treatments for IBS.”
BackgroundInfluential
Irritable bowel syndrome: Epidemiology, diagnosis and treatment: An update for health‐care practitioners
Grundmann, O., & Yoon, S. L. (2010) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2009.06120.x · Cited by 210 · see citing works
Health-Related Quality of Life and Cost Impact of Irritable Bowel Syndrome in a UK Primary Care Setting
Akehurst, R. L., Brazier, J. E., Mathers, N. J., Keefe, C. O., Kaltenthaler, E., Morgan, A., Platts, M., & Walters, S. J. (2002) · PharmacoEconomics · doi:10.2165/00019053-200220070-00003 · Cited by 203 · see citing works
The efficacy of ATCC 55730 in the treatment of patients with irritable bowel syndrome—a double blind, placebo-controlled, randomized study
NIV, E., NAFTALI, T., HALLAK, R., & VAISMAN, N. (2005) · Clinical Nutrition · doi:10.1016/j.clnu.2005.06.001 · Cited by 191 · see citing works
Lactobacillus paracasei normalizes muscle hypercontractility in a murine model of postinfective gut dysfunction
Verdú, E. F., Bercík, P., Bergonzelli, G. E., Huang, X.-X., Blennerhasset, P., Rochat, F., Fiaux, M., Mansourian, R., Corthésy-Theulaz, I., & Collins, S. M. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.06.007 · Cited by 180 · see citing works
Prevalence and temporal stability of selected clostridial groups in irritable bowel syndrome in relation to predominant faecal bacteria
Maukonen, J., Satokari, R., Mättö, J., Söderlund, H., Mattila-Sandholm, T., & Saarela, M. (2006) · Journal of Medical Microbiology · doi:10.1099/jmm.0.46134-0 · Cited by 156 · see citing works
Small intestinal transit, absorption, and permeability in patients with AIDS with and without diarrhoea
Sharpstone, D., Neild, P., Crane, R., Taylor, C. M., Hodgson, C., Sherwood, R., Gazzard, B., & Bjarnason, I. (1999) · Gut · doi:10.1136/gut.45.1.70 · Cited by 155 · see citing works
Self-citation
The Evidence to Support Health Claims for Probiotics
Farnworth, E. R. (2008) · Journal of Nutrition · doi:10.1093/jn/138.6.1250s · Cited by 135 · cited 1× · see citing works
“The vast majority of these trials were not considered of sufficient quality to be included in two recent meta-analyses, 22 or to support valid health claims to the standards required by food standard agencies.(23) However, despite the methodological limitations of many of these trials, both meta-analyses concluded tha…”
Background
A Global Perspective on Irritable Bowel Syndrome
Quigley, E. M. M., Abdel-Hamid, H., Barbara, G., Bhatia, S. J., Boeckxstaens, G. E., GIORGIO, R. D., Delvaux, M. M., Drossman, D. A., Foxx–Orenstein, A. E., Guarner, F., et al. (2012) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e318247157c · Cited by 131 · cited 2× · see citing works
“Accordingly, in the UK, the prevalence of IBS is reported to be 12% using Rome II diagnostic criteria and 22% using Manning criteria.(2)”
Method
Measuring irritable bowel syndrome patient‐reported outcomes with an abdominal pain numeric rating scale
Spiegel, B. M. R., Bolus, R. R., Harris, L. A., Lucak, S. L., Naliboff, B. D., Esrailian, E., Chey, W. D., Lembo, A. J., Karsan, H. A., Tillisch, K., et al. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.04144.x · Cited by 112 · cited 1× · see citing works
“by the original authors of the IBS-SSS as a change of ≥50 points(24) and by a later group as ≥95 points.(26) As far as we are aware these are the only definitions of MCID for IBS in the literature.”
Method
[A meta-analysis of probiotics for the treatment of irritable bowel syndrome].
Hu, Y., Tao, L., & Lyu, B. (2015) · Zhonghua nei ke za zhi · doi:10.3760/cma.j.issn.0578-1426.2015.05.014 · Cited by 111
Non-colonic features of irritable bowel syndrome
Chou, A. F. (1986) · Annals of Emergency Medicine · doi:10.1016/s0196-0644(86)80164-0 · Cited by 103 · see citing works
Bugs and irritable bowel syndrome: The good, the bad and the ugly
Ghoshal, U. C., Park, H., & Gwee, K. (2010) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2009.06133.x · Cited by 88 · see citing works
Clinical Trial on the Efficacy of a New Symbiotic Formulation, Flortec, in Patients With Irritable Bowel Syndrome: A Multicenter, Randomized Study
Andriulli, A., Neri, M., Loguercio, C., Terreni, N., Merla, A., Cardarella, M. P., Federico, A., Chilovi, F., Milandri, G. L., De Bona, M., et al. (2008) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e31817fadd6 · Cited by 75 · see citing works
Developing Valid and Reliable Health Utilities in Irritable Bowel Syndrome: Results From the IBS PROOF Cohort
Spiegel, B. M. R., Harris, L. A., Lucak, S. L., Mayer, E. A., Naliboff, B. D., Bolus, R. R., Esrailian, E., Chey, W. D., Lembo, A. J., Karsan, H. A., et al. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.232 · Cited by 74 · cited 1× · see citing works
“recent analysis, which is similar to that of Class 3 congestive heart failure and rheumatoid arthritis.(7) The majority of patients with IBS self-medicate with over the counter preparations or are managed by primary care physicians; only the more severe cases are referred for”
Result
Short‐term stability of subtypes in the irritable bowel syndrome: prospective evaluation using the Rome III classification
Engsbro, A. L., Simrén, M., & Bytzer, P. M. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04948.x · Cited by 64 · cited 1× · see citing works
“subtype over time and suggest that a consistent stool pattern sub-classification requires a 2 week assessment.(37)”
Background
Lactobacillus rhamnosus GG and Bifidobacterium animalis MB5 induce intestinal but not systemic antigen-specific hyporesponsiveness in ovalbumin-immunized rats.
Finamore, A., Roselli, M., Britti, M. S., Merendino, N., & Mengheri, E. (2012) · Journal of NutriLife · doi:10.3945/jn.111.148924 · Cited by 41 · see citing works
The Economic Consequences of Irritable Bowel Syndrome
Leong, S. A., Barghout, V. E., Birnbaum, H. G., Thibeault, C., Ben-Hamadi, R., Frech, F. H., & Ofman, J. J. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.8.929 · cited 1×
“Taken collectively, the symptoms of IBS may impact significantly on quality of life (QOL) and result in substantial increased direct health care costs, 5 as well as indirect costs such as absenteeism from work.(6) The health utility of severe IBS [where utility is a measure of health-related QOL on a scale of 0 (death…”
Background
Management of irritable bowel syndrome in primary care
Olano, C., López‐Colombo, A., & Schmulson, M. (2013) · doi:10.2217/ebo.13.525 · cited 2×
“mon gastrointestinal conditions with an estimated prevalence of between 10% and 20% in most countries.(1)”
Background

Flagged first, then by citations

1 of the 45 references couldn’t be matched to a known paper.

Sorted by citations

Systematic review with meta‐analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome
Ford, A. C., Harris, L. A., Lacy, B. E., Quigley, E. M. M., & Moayyedi, P. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15001 · Cited by 619 · see citing works
“The 53 RCTs of probiotics in IBS involved 5545 patients.(32-49,53-87) The proportion of women in trials ranged between 9% and 100%.”
Background
American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome
Ford, A. C., Moayyedi, P., Chey, W. D., Harris, L. A., Lacy, B. E., Saito, Y. A., & Quigley, E. M. M. (2018) · American Journal of Gastroenterology · doi:10.1038/s41395-018-0084-x · Cited by 388 · see citing works
Stress and the Microbiota–Gut–Brain Axis in Visceral Pain: Relevance to Irritable Bowel Syndrome
Moloney, R. D., Johnson, A. C., O’Mahony, S. M., Dinan, T. G., Meerveld, B. G., & Cryan, J. F. (2015) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12490 · Cited by 396 · see citing works
British Dietetic Association systematic review and evidence‐based practice guidelines for the dietary management of irritable bowel syndrome in adults (2016 update)
McKenzie, Y. A., Bowyer, R. K., Leach, H., Gulia, P., Horobin, J., O'Sullivan, N.-A., Pettitt, C., Reeves, L., Seamark, L., Williams, M., et al. (2016) · Journal of Human Nutrition and Dietetics · doi:10.1111/jhn.12385 · Cited by 361 · see citing works
The food-gut axis: lactic acid bacteria and their link to food, the gut microbiome and human health
De Filippis, F., Pasolli, E., & Ercolini, D. (2020) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuaa015 · Cited by 303 · see citing works
Beneficial effect of butyrate‐producing Lachnospiraceae on stress‐induced visceral hypersensitivity in rats
Zhang, J., Song, L., Wang, Y., Liu, C., Zhang, L., Zhu, S., Liu, S., & Duan, L. (2018) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.14536 · Cited by 292 · see citing works
The influence of the gut microbiome on obesity, metabolic syndrome and gastrointestinal disease
Parekh, P. J., Balart, L. A., & Johnson, D. A. (2015) · Clinical and Translational Gastroenterology · doi:10.1038/ctg.2015.16 · Cited by 219 · see citing works
Microbiome-based interventions to modulate gut ecology and the immune system
Hitch, T. C. A., Hall, L. J., Walsh, S. K., Leventhal, G. E., Slack, E. M. C., de Wouters, T., Walter, J., & Clavel, T. (2022) · Mucosal Immunology · doi:10.1038/s41385-022-00564-1 · Cited by 251 · see citing works
The Role of Visceral Hypersensitivity in Irritable Bowel Syndrome: Pharmacological Targets and Novel Treatments
Farzaei, M. H., Bahramsoltani, R., Abdollahi, M. R., & Rahimi, R. (2016) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm16001 · Cited by 209 · see citing works
“4 October, 2016 (558-574) probiotic product containing Lactobacillus rhamnosus, Lactobacillus plantarum, Lactobacillus acidophilus, and Enterococcus faecium could enhance patient satisfaction due to decrease in abdominal pain.(115) On the contrary, in a randomized, double-blind, placebocontrolled setting, Roberts et a…”
Background
World Gastroenterology Organisation Global Guidelines: Probiotics and Prebiotics
Guarner, F., Sanders, M. E., Szajewska, H., Cohen, H., Eliakim, R., Herrera-deGuise, C., Karakan, T., Merenstein, D., Piscoya, A., Ramakrishna, B., et al. (2024) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000002002 · Cited by 209 · see citing works
Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Irritable Bowel Syndrome (IBS)
Moayyedi, P., Andrews, C., MacQueen, G., Korownyk, C., Marsiglio, M., Graff, L., Kvern, B., Lazarescu, A., Liu, L. W. C., Paterson, W., et al. (2019) · Journal of the Canadian Association of Gastroenterology · doi:10.1093/jcag/gwy071 · Cited by 182 · see citing works
A randomised, double-blind, placebo-controlled trial of a multi-strain probiotic in patients with asymptomatic ulcerative colitis and Crohn’s disease
Bjarnason, I., Sission, G., & Hayee, B. (2019) · Inflammopharmacology · doi:10.1007/s10787-019-00595-4 · Cited by 209 · see citing works
Self-citation
Effects of probiotic type, dose and treatment duration on irritable bowel syndrome diagnosed by Rome III criteria: a meta-analysis
Zhang, Y., Li, L., Guo, C., Mu, D., Feng, B., Zuo, X., & Li, Y. (2016) · BMC Gastroenterology · doi:10.1186/s12876-016-0470-z · Cited by 180 · see citing works
“[49] UK Single-centre 186/124 Symprove containing four strains of bacteria: Lactobacillus rhamnosus, Lactobacillus plantarum, Lactobacillus acidophilus, and Enterococcus faecium 10(10) 12 Response (IBS-SSS)”
Background
Systematic review: Probiotics in the management of lower gastrointestinal symptoms—An updated evidence-based international consensus
Hungin, A. P. S., Mitchell, C. R., Whorwell, P., Mulligan, C., Cole, O., Agréus, L., Fracasso, P., Lionis, C., Mendive, J., Philippart de Foy, J. ‐., et al. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14539 · Cited by 154 · see citing works
Gut Microbiota as Potential Orchestrators of Irritable Bowel Syndrome
Bennet, S., Öhman, L., & Simrén, M. (2015) · Gut and Liver · doi:10.5009/gnl14344 · Cited by 143 · see citing works
Gastrointestinal dysfunction in Parkinson’s disease: Molecular pathology and implications of gut microbiome, probiotics, and fecal microbiota transplantation
Metta, V., Leta, V., Mrudula, K. R., Prashanth, L. K., Goyal, V., Borgohain, R., Chung-Faye, G., & Chaudhuri, K. R. (2022) · Journal of Neurology · doi:10.1007/s00415-021-10567-w · Cited by 130 · see citing works
Bifidobacterium longum and Lactobacillus helveticus Synergistically Suppress Stress-related Visceral Hypersensitivity Through Hypothalamic-Pituitary-Adrenal Axis Modulation
Ait-Belgnaoui, A., Payard, I., Rolland, C., Harkat, C., Braniste, V., Théodorou, V., & Tompkins, T. A. (2018) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm16167 · Cited by 139 · see citing works
Probiotics in Irritable Bowel Syndrome: An Up-to-Date Systematic Review
Dale, H. F., Rasmussen, S. H., Asiller, Ö. Ö., & Lied, G. A. (2019) · Nutrients · doi:10.3390/nu11092048 · Cited by 169 · see citing works
The effect of Clostridium butyricum on symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial
Sun, Y.-Y., Li, M., Li, Y.-Y., Li, L.-X., Zhai, W.-Z., Wang, P., Yang, X.-X., Gu, X., Song, L.-J., Li, Z., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-21241-z · Cited by 126 · see citing works
A four-strain probiotic exerts positive immunomodulatory effects by enhancing colonic butyrate production in vitro
Moens, F., den Abbeele, P. V., Basit, A. W., Dodoo, C. C., Chatterjee, R., Smith, B., & Gaisford, S. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.11.020 · Cited by 135 · see citing works
Lactobacillus casei DG and its postbiotic reduce the inflammatory mucosal response: an ex-vivo organ culture model of post-infectious irritable bowel syndrome
Compare, D., Rocco, A., Coccoli, P., Angrisani, D., Sgamato, C., Iovine, B., Salvatore, U., & Nardone, G. (2017) · BMC Gastroenterology · doi:10.1186/s12876-017-0605-x · Cited by 133 · see citing works
Lacto-fermented sauerkraut improves symptoms in IBS patients independent of product pasteurisation-a pilot study
Nielsen, E. S., Garnås, E., Jensen, K. J., Hansen, L. H., Olsen, P. S., Ritz, C., Krych, L., & Nielsen, D. S. (2018) · Food & Function · doi:10.1039/c8fo00968f · Cited by 113 · see citing works
A randomized placebo-controlled clinical trial of a multi-strain probiotic formulation (Bio-Kult®) in the management of diarrhea-predominant irritable bowel syndrome
Ishaque, S. M., Khosruzzaman, S. M., Ahmed, D. S., & Sah, M. P. (2018) · BMC Gastroenterology · doi:10.1186/s12876-018-0788-9 · Cited by 109 · see citing works
AGA Technical Review on the Role of Probiotics in the Management of Gastrointestinal Disorders
Preidis, G. A., Weizman, A. V., Kashyap, P., & Morgan, R. L. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.05.060 · Cited by 135 · see citing works
Irritable bowel syndrome symptom severity improves equally with probiotic and placebo
Lyra, A., Hillilä, M., Huttunen, T., Männikkö, S., Taalikka, M., Tennilä, J., Tarpila, A., Lahtinen, S., Ouwehand, A. C., & Veijola, L. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i48.10631 · Cited by 106 · see citing works
Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial
Ford, A. C., Wright-Hughes, A. M., Alderson, S. L., Ow, P.-L., Ridd, M. J., Foy, R., Bianco, G., Bishop, F. L., Chaddock, M., Cook, H., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01523-4 · Cited by 157 · see citing works
“…provided 90% power to detect a minimum clinically important difference of 35 points between amitriptyline and placebo at 6 months on the IBS-SSS, as proposed in a previous trial of cognitive behavioural therapy in IBS, 42,43 assuming a maximum IBS-SSS SD of 110 points, 44,45 with 5% significance.”
The kinetics of gut microbial community composition in patients with irritable bowel syndrome following fecal microbiota transplantation
Mazzawi, T., Lied, G. A., Sangnes, D. A., El-Salhy, M., Hov, J. R., Gilja, O. H., Hatlebakk, J. G., & Hausken, T. (2018) · PLoS ONE · doi:10.1371/journal.pone.0194904 · Cited by 92 · see citing works
British Dietetic Association systematic review of systematic reviews and evidence‐based practice guidelines for the use of probiotics in the management of irritable bowel syndrome in adults (2016 update)
McKenzie, Y. A., Thompson, J., Gulia, P., & Lomer, M. C. E. (2016) · Journal of Human Nutrition and Dietetics · doi:10.1111/jhn.12386 · Cited by 80 · see citing works
“Fourteen RCTs showed statistically significant improvements for adequate symptom relief (38,39,42,54,57,58,68), a VAS (45,49,50,55,56) or the IBS-SSS (65,67).”
BackgroundMethodInfluential
The Effectiveness and Safety of Multi-Strain Probiotic Preparation in Patients with Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized Controlled Study
Skrzydło-Radomańska, B., Prozorow-Król, B., Cichoż‐Lach, H., Majsiak, E., Bierła, J. B., Kanarek, E., Sowińska, A., & Cukrowská, B. (2021) · Nutrients · doi:10.3390/nu13030756 · Cited by 88 · see citing works
“Our results are consistent with the findings that multispecies combinations of probiotic strains have significant effects on IBS symptoms [28,29,37,38].”
BackgroundResultInfluential
The Role of Bacteria, Probiotics and Diet in Irritable Bowel Syndrome
Harper, A. J., Naghibi, M., & Garcha, D. S. (2018) · Foods · doi:10.3390/foods7020013 · Cited by 77 · see citing works
“Sisson 2014 [92] 186 * 4-strains (1 × 1010 at 1 mL/kg) 50 mL contains 10 billion CFU 1 mL = 200 million CFU (NB: average adult female = 70 kg, average male = 80 kg; therefore = 14–16 billion CFU/day) 12 weeks”
The Role of the Human Microbiome in the Pathogenesis of Pain
Ustianowska, K., Ustianowski, Ł., Machaj, F., Gorący, A., Rosik, J., Szostak, B., Szostak, J., & Pawlik, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113267 · Cited by 75 · see citing works
“, Symprove, a probiotic containing three Lactobacillus types and one Enterococcus, was shown to improve symptom severity in IBS [96].”
Background
Efficacy and Safety of Probiotics in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis
Li, B., Li, L., Deng, H., Guo, J., Shu, H., & Zhang, L. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00332 · Cited by 95 · see citing works
“…et al., 2012; Kruis et al., 2012; Begtrup et al., 2013; Roberts et al., 2013; Jafari et al., 2014; Lorenzo-Zuniga et al., 2014; Ludidi et al., 2014; Sisson et al., 2014; Yoon et al., 2014; Pineton de Chambrun et al., 2015; Yoon et al., 2015; Spiller et al., 2016;Mezzasalma et al., 2016; Thijssen…”
BackgroundMethodInfluential
Probiotic Therapy of the Irritable Bowel Syndrome: Why Is the Evidence Still Poor and What Can Be Done About It?
Mazurak, N., Broelz, E. K., Storr, M., & Enck, P. (2015) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm15071 · Cited by 72 · see citing works
Update S3-Leitlinie Reizdarmsyndrom: Definition, Pathophysiologie, Diagnostik und Therapie. Gemeinsame Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft für Neurogastroenterologie und Motilität (DGNM) – Juni 2021 – AWMF-Registriernummer: 021/016
Layer, P., Andresen, V., Allescher, H. ‐., Bischoff, S. C., Claßen, M., Elsenbruch, S., Freitag, M., Frieling, T., Gebhard, M., Goebel‐Stengel, M., et al. (2021) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1591-4794 · Cited by 78 · see citing works
A 4-strain probiotic supplement influences gut microbiota composition and gut wall function in patients with ulcerative colitis
Ghyselinck, J., Verstrepen, L., Moens, F., den Abbeele, P. V., Said, J., Smith, B., Bjarnason, I., Basit, A. W., & Gaisford, S. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119648 · Cited by 71 · see citing works
Self-citation
Fibromyalgia and Irritable Bowel Syndrome Interaction: A Possible Role for Gut Microbiota and Gut-Brain Axis
Garofalo, C., Cristiani, C. M., Ilari, S., Passacatini, L. C., Malafoglia, V., Viglietto, G., Maiuolo, J., Oppedisano, F., Palma, E., Tomino, C., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11061701 · Cited by 64 · see citing works
Guidelines on the management of irritable bowel syndrome
Pietrzak, A. M., Skrzydło-Radomańska, B., Mulak, A., Lipiński, M., Malecka-Panas, E. I., Reguła, J., & Rydzewska, G. M. (2018) · Gastroenterology Review · doi:10.5114/pg.2018.78343 · Cited by 56 · see citing works
The Efficacy of Probiotics, Prebiotics, Synbiotics, and Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Systematic Review and Network Meta-Analysis
Wu, Y., Li, Y., Zheng, Q., & Li, L. (2024) · Nutrients · doi:10.3390/nu16132114 · Cited by 66 · see citing works
Efficacy and Safety of Probiotics, Prebiotics and Synbiotics in the Treatment of Irritable Bowel Syndrome: A systematic review and meta-analysis
Asha, M. Z., & Khalil, S. F. H. (2020) · Sultan Qaboos University medical journal · doi:10.18295/squmj.2020.20.01.003 · Cited by 85 · see citing works
Clostridium butyricum alleviates intestinal low-grade inflammation in TNBS-induced irritable bowel syndrome in mice by regulating functional status of lamina propria dendritic cells
Zhao, Q. P., Yang, W.-R., Wang, X.-H., Li, G., Xu, L., Cui, X., Liu, Y., & Zuo, X. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i36.5469 · Cited by 71 · see citing works
The Role of the Gastrointestinal Microbiota in Visceral Pain
Rea, K., O’Mahony, S. M., Dinan, T. G., & Cryan, J. F. (2016) · Handbook of experimental pharmacology · doi:10.1007/164_2016_115 · Cited by 62 · see citing works
Influence of probiotic bacteria on gut microbiota composition and gut wall function in an in-vitro model in patients with Parkinson's disease
Ghyselinck, J., Verstrepen, L., Moens, F., den Abbeele, P. V., Bruggeman, A., Said, J., Smith, B., Barker, L. A., Jordan, C., Leta, V., et al. (2021) · International Journal of Pharmaceutics X · doi:10.1016/j.ijpx.2021.100087 · Cited by 58 · see citing works
Probiotics Improve Eating Disorders in Mandarin Fish (Siniperca chuatsi) Induced by a Pellet Feed Diet via Stimulating Immunity and Regulating Gut Microbiota
Chen, X., Yi, H., Liu, S., Zhang, Y., Su, Y., Liu, X., Bi, S., Lai, H., Zeng, Z., & Li, G. (2021) · Microorganisms · doi:10.3390/microorganisms9061288 · Cited by 54 · see citing works
Efficacy of combination therapy with probiotics and mosapride in patients with<scp>IBS</scp>without diarrhea: a randomized, double‐blind, placebo‐controlled, multicenter, phase II trial
Choi, C. H., Kwon, J. G., Kim, S. K., Myung, S. ‐., Park, K. S., Sohn, C. ‐., Rhee, P. ‐., Lee, K. J., Lee, O. Y., Jung, H. ‐., et al. (2015) · Neurogastroenterology & Motility · doi:10.1111/nmo.12544 · Cited by 46 · see citing works
Effect of a Preparation of Four Probiotics on Symptoms of Patients with Irritable Bowel Syndrome: Association with Intestinal Bacterial Overgrowth
Leventogiannis, K., Gkolfakis, P., Spithakis, G., Tsatali, A., Pistiki, A. C., Sioulas, A. D., Giamarellos‐Bourboulis, E. J., & Τriantafyllou, Κ. (2018) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-018-9401-3 · Cited by 48 · see citing works
Probiotics, Prebiotics, and Synbiotics in the Irritable Bowel Syndrome Treatment: A Review
Chlebicz-Wójcik, A., & Śliżewska, K. (2021) · Biomolecules · doi:10.3390/biom11081154 · Cited by 51 · see citing works
Effectiveness and Safety of Probiotics for Patients with Constipation-Predominant Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of 10 Randomized Controlled Trials
Shang, X., E, F.-F., Guo, K.-L., Li, Y.-F., Zhao, H.-L., Wang, Y., Chen, N., Nian, T., Yang, C.-Q., Yang, K.-H., et al. (2022) · Nutrients · doi:10.3390/nu14122482 · Cited by 41 · see citing works
Outcome-Specific Efficacy of Different Probiotic Strains and Mixtures in Irritable Bowel Syndrome: A Systematic Review and Network Meta-Analysis
Xie, P., Luo, M., Deng, X., Fan, J., & Xiong, L. (2023) · Nutrients · doi:10.3390/nu15173856 · Cited by 45 · see citing works
Efficacy and safety of probiotics in irritable bowel syndrome: A systematic review and meta-analysis
Jia, L.-Q., Sun, J.-R., Kong, C.-F., Qu, X.-K., Deng, C., & Lou, Y.-N. (2020) · Saudi Journal of Gastroenterology · doi:10.4103/sjg.sjg_384_19 · Cited by 40 · see citing works
“Finally, five RCTs reported the effect of probiotics on quality of life (Qol) in 856 patients.[28,33,43,49,51] There was no apparent benefit detected for probiotics (SMD = ‐0.”
Background
Clinical response to fecal microbiota transplantation in patients with diarrhea-predominant irritable bowel syndrome is associated with normalization of fecal microbiota composition and short-chain fatty acid levels
Mazzawi, T. R. E., Hausken, T., Hov, J. R., Valeur, J., Sangnes, D. A., El‐Salhy, M., Gilja, O. H., Hatlebakk, J. G., & Lied, G. A. (2019) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2019.1624815 · Cited by 42 · see citing works
“The role of gut microbiota alterations in IBS has led to increased interest in using probiotic [2] and antibiotic [3] approaches for improving IBS symptoms [2].”
Background
A Systematic Review of Probiotic Interventions for Gastrointestinal Symptoms and Irritable Bowel Syndrome in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME)
Corbitt, M., Campagnolo, N., Staines, D., & Marshall‐Gradisnik, S. (2018) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-018-9397-8 · Cited by 37 · see citing works
The Effect of Probiotics on Quality of Life, Depression and Anxiety in Patients with Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis
de Sequeira, C. L. M., Kaeber, M., Cekin, S., Enck, P., & Mack, I. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10163497 · Cited by 44 · see citing works
“…et al. (2018) Martoni et al. (2020) Niv et al. (2005) O'Mahony et al. (2005) Pinto-Sanchez et al. (2017) Preston et al. (2018) Simren et al. (2010) Sisson et al. (2014) Staudacher et al. (2017) Stevenson et al. (2014) Sun et al. (2018) Thijssen et al. (2016) Whorwell et al. (2006) Wong et al.…”
A randomized double-blind placebo-controlled trial of a multi-strain probiotic in treatment of symptomatic uncomplicated diverticular disease
Kvasnovsky, C., Bjarnason, I., Donaldson, N., Sherwood, R. A., & Papagrigoriadis, S. (2017) · Inflammopharmacology · doi:10.1007/s10787-017-0363-y · Cited by 39 · see citing works
“Symprove is a liquid multi-strain probiotic that has been beneficial in reducing symptom scores in patients with classic IBS (Sisson et al. 2014).”
InfluentialSelf-citation
Immunological Biomarkers in Postinfectious Irritable Bowel Syndrome
Pike, B. L., Paden, K. A., Alcala, A. N., Jaep, K. M., Gormley, R. P., Maue, A. C., Christmann, B. S., Elson, C. O., Riddle, M. S., & Porter, C. K. (2015) · Journal of Travel Medicine · doi:10.1111/jtm.12218 · Cited by 42 · see citing works
Probiotics in functional bowel disorders
Hod, K., & Ringel, Y. (2016) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2016.01.003 · Cited by 33 · see citing works
Editorial: The Importance of Systematic Reviews and Meta-Analyses of Probiotics and Prebiotics
Whelan, K. (2014) · The American Journal of Gastroenterology · doi:10.1038/ajg.2014.258 · Cited by 29 · see citing works
A narrative review on the use of probiotics in several diseases. Evidence and perspectives
Campaniello, D., Bevilacqua, A., Speranza, B., Racioppo, A., Sinigaglia, M., & Corbo, M. R. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1209238 · Cited by 36 · see citing works
How can probiotic improve irritable bowel syndrome symptoms?
Horvat, I. B., Gobin, I., Kresović, A., & Hauser, G. (2021) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.v13.i9.923 · Cited by 35 · see citing works
Gut microbiota and irritable bowel syndrome
Zhao, Y., & Zou, D. (2023) · Journal of Digestive Diseases · doi:10.1111/1751-2980.13204 · Cited by 29 · see citing works
“Furthermore, some have reported a delayed effect of multispecies probiotics in IBS treatment.(69) Multistrain probiotics possess the qualities of being time-, dose-, and target-dependent in IBS”
Background
Evaluating the Efficacy of Probiotics in IBS Treatment Using a Systematic Review of Clinical Trials and Multi-Criteria Decision Analysis
Ceccherini, C., Daniotti, S., Bearzi, C., & Re, I. (2022) · Nutrients · doi:10.3390/nu14132689 · Cited by 35 · see citing works
The Gut Microbiota and Chronic Pain
Pak, R. J., Cho, M. S., Pride, K., & Abd-Elsayed, A. A. (2024) · Current Pain and Headache Reports · doi:10.1007/s11916-024-01221-x · Cited by 23 · see citing works
“Other studies examining the effects of multispecies probiotics on symptoms of IBS, including abdominal pain, showed significant reductions in pain as well [69, 70].”
Preventive effects of probiotics on dental caries in vitro and in vivo
Zhang, J., Wang, Q., & Duan, Z. (2024) · BMC Oral Health · doi:10.1186/s12903-024-04703-x · Cited by 24 · see citing works
“Probiotics have been recognized in regulating gut health [13–15], and there also can be effective in oral health [16, 17].”
Background
Low FODMAP Diet and Probiotics in Irritable Bowel Syndrome: A Systematic Review With Network Meta-analysis
Xie, C.-R., Tang, B., Shi, Y., Peng, W.-Y., Ye, K., Tao, Q., Yu, S., Zheng, H., & Chen, M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.853011 · Cited by 26 · see citing works
“Thirty-one trials assessed a combination of probiotics (Kim et al., 2003; Kim et al., 2005; Kajander et al., 2005; Kim et al., 2006; Guyonnet et al., 2007; Zeng et al., 2008; Drouault–Holowacz et al., 2008; Kajander et al., 2008; Williams et al., 2009; Hong et al., 2009; Simren et al., 2010; Sondergaard et al., 2011;…”
Background
Probiotics for the management of irritable bowel syndrome: a systematic review and three-level meta-analysis
Chen, M., Lu, Y., Xie, C.-R., Wang, X., Feng, S., Xiao, X.-Y., & Zheng, H. (2023) · International Journal of Surgery · doi:10.1097/js9.0000000000000658 · Cited by 32 · see citing works
“The model – included 23 studies [20,22,23,28,33,36 – 38, 40, 43 , 48, 56, 60, 61 The moderator analysis showed that the treatment duration and the types of probiotics affected the effect size.”
MethodInfluential
Survival of Enterococcus faecium, Staphylococcus aureus and Pseudomonas aeruginosa on cotton
Fijan, S., Pahor, D., & Šostar-Turk, S. (2017) · Textile Research Journal · doi:10.1177/0040517516658514 · Cited by 22 · see citing works
Effects of a Four‐Strain Probiotic on Gut Microbiota, Inflammation, and Symptoms in Parkinson's Disease: A Randomized Clinical Trial
Leta, V., Zinzalias, P., Batzu, L., Mandal, G., Staunton, J., Jernstedt, F., Rosqvist, K., Timpka, J., van Vliet, T., Trivedi, D., et al. (2025) · Movement Disorders · doi:10.1002/mds.70047 · Cited by 21 · see citing works
Acacia fiber or probiotic supplements to relieve gastrointestinal complaints in patients with constipation-predominant IBS: a 4-week randomized double-blinded placebo-controlled intervention trial
JanssenDuijghuijsen, L. M., van den Belt, M., Rijnaarts, I., Vos, A. P., Guillemet, D., Witteman, B. J. M., & de Wit, N. J. W. (2024) · European Journal of Nutrition · doi:10.1007/s00394-024-03398-8 · Cited by 18 · see citing works
“…on the IBS-SSS after 4 weeks probiotic BLa80 treatment in significantly more (53% probiotic vs. 29% placebo) patients is consid - ered a clinical meaningful change [ 23], and is comparable or even higher compared to studies with a longer treatment period using other probiotic strains [41– 43].”
Result
Effects of the probiotic Lactiplantibacillus plantarum IMC 510® on body composition, biochemical parameters, gut microbiota composition and function, and clinical symptoms of overweight/obese subjects
Pagliai, G., Coman, M. M., Baldi, S., Dinu, M., Nannini, G., Russo, E., Curini, L., Colombini, B., Lotti, S., Pallecchi, M., et al. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1142527 · Cited by 18 · see citing works
Effect of Personalized Prebiotic and Probiotic Supplements on the Symptoms of Irritable Bowel Syndrome: An Open-Label, Single-Arm, Multicenter Clinical Trial
Matsuura, N., Kanayama, M., Watanabe, Y., Yamada, H., Lili, L., & Torii, A. (2024) · Nutrients · doi:10.3390/nu16193333 · Cited by 16 · see citing works
“For example, several randomized controlled trials (RCTs) involving patients with IBS who received probiotic formulations have indicated an improvement in the severity of IBS symptoms [12–17].”
Background
Methods of Determining Irritable Bowel Syndrome and Efficiency of Probiotics in Treatment: A Review
Ahlawat, G. M., & Singh, P. K. (2023) · Current Therapeutic Research · doi:10.1016/j.curtheres.2023.100721 · Cited by 13 · see citing works
“1 , 35 The objective of this investigation was to scrutinize the inﬂu-ence of multistrain probiotics on patients with IBS patients with diarrhea.”
Background
Nocebo response intensity and influencing factors in the randomized clinical trials of irritable bowel syndrome: A systematic review and meta-analysis
Li, R., Chen, F., He, X., Feng, Y., Pei, Q., Wang, D., Liu, X., Liu, J., Hou, X., & Bai, T. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1018713 · Cited by 14 · see citing works
The Effect of Anaerobically Cultivated Human Intestinal Microbiota Compared to Fecal Microbiota Transplantation on Gut Microbiota Profile and Symptoms of Irritable Bowel Syndrome, a Double-Blind Placebo-Controlled Study
Mazzawi, T. R. E., Hausken, T., Refsnes, P. F., Hatlebakk, J. G., & Lied, G. A. (2022) · Microorganisms · doi:10.3390/microorganisms10091819 · Cited by 20 · see citing works
Efficacy and Safety of a Novel Herbal Medicine in the Treatment of Irritable Bowel Syndrome: A Randomized Double-Blinded Clinical Trial
Bordbar, G., Miri, M. B., Omidi, M., Shoja, S., & Akhavan, M. (2020) · Gastroenterology Research and Practice · doi:10.1155/2020/8213082 · Cited by 12 · see citing works
Evaluation of the efficacy of probiotics as treatment in irritable bowel syndrome
Ruiz-Sánchez, C., Escudero‐López, B., & Fernández‐Pachón, M. (2024) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2024.01.003 · Cited by 14 · see citing works
The Effects of Fecal Microbiota Transplantation on the Symptoms and the Duodenal Neurogenin 3, Musashi 1, and Enteroendocrine Cells in Patients With Diarrhea-Predominant Irritable Bowel Syndrome
Mazzawi, T. R. E., El‐Salhy, M., Lied, G. A., & Hausken, T. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.524851 · Cited by 12 · see citing works
“This may also have shed some light on the mechanisms lying behind FMT and the positive effects of using these bacterial strains in the management of IBS symptoms (Whorwell et al., 2006; Drouault-Holowacz et al., 2008; Bixquert Jimenez, 2009; Sisson et al., 2014).”
Background
Focus on the use of antidepressants to treat pediatric functional abdominal pain: current perspectives
Bonilla, S., & Nurko, S. (2018) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s146646 · Cited by 17 · see citing works
Advances in Probiotics for Sustainable Food and Medicine
Joshi, M. (2021) · doi:10.1007/978-981-15-6795-7 · Cited by 12
Effects of Probiotics and Diet Management in Patients With Irritable Bowel Syndrome: A Systematic Review and Network Meta-analysis
Lei, Y., Sun, X., Ruan, T., Lu, W., Deng, B., Zhou, R., & Mu, D. (2024) · Nutrition Reviews · doi:10.1093/nutrit/nuae217 · Cited by 12 · see citing works
Effect of Bifidobacterium bifidum G9-1 on the Intestinal Environment and Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)-like Symptoms in Patients with Quiescent Crohn’s Disease: A Prospective Pilot Study
Tomita, T., Fukui, H., Okugawa, T., Nakanishi, T., Mieno, M., Nakai, K., Eda, H., Kitayama, Y., Oshima, T., Shinzaki, S., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12103368 · Cited by 11 · see citing works
Use of a water-based probiotic to treat common gut pathogens
Dodoo, C. C., Stapleton, P. D., Basit, A. W., & Gaisford, S. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.11.075 · Cited by 12 · see citing works
Drug discovery approaches to irritable bowel syndrome
Hornby, P. J. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1049528 · Cited by 11 · see citing works
“An example of conflicting data are in two recent placebo-controlled trials in small numbers of IBS patients where one yielded no beneficial effects on the symptoms of visceral hypersensitivity [57] but in another trial, the IBS symptom severity score and quality of life were both improved [58].”
Result
Efficacy of Probiotics in the Management of Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis
Almabruk, B. A., Bajafar, A. A., Mohamed, A., Al-Zahrani, S. A., Albishi, N. M., Aljarwan, R. M., Aljaser, R. A., Alghamdi, L. I., Almutairi, T., Alsolami, A. S., et al. (2024) · Cureus · doi:10.7759/cureus.75954 · Cited by 4 · see citing works
Amitriptyline at low-dose and titrated for irritable bowel syndrome as second-line treatment (The ATLANTIS trial): protocol for a randomised double-blind placebo-controlled trial in primary care
Alderson, S. L., Wright-Hughes, A. M., Ford, A. C., Farrin, A. J., Hartley, S., Fernandez, C., Taylor, C., Ow, P. L., Teasdale, E. J., Howdon, D., et al. (2022) · Trials · doi:10.1186/s13063-022-06492-6 · Cited by 11 · see citing works
“Sample size A sample size of 414 evaluable patients will provide 90% power to detect the minimum clinically important between-group difference of 35 points on the IBS-SSS [37], between amitriptyline and placebo at 6 months, assuming a standard deviation of 110 points [38, 39] and 5% significance level.”
Background
Kinetic analysis of microcalorimetric data derived from microbial growth: Basic theoretical, practical and industrial considerations.
Cabadaj, M., Bashir, S., Haskins, D., Said, J., McCoubrey, L. E., Gaisford, S., & Beezer, A. (2021) · Journal of Microbiological Methods · doi:10.1016/j.mimet.2021.106276 · Cited by 10
Microbes as Drugs: The Potential of Pharmabiotics
LeBegue, C. E., Love, B. L., & Wyatt, M. D. (2019) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2357 · Cited by 13 · see citing works
Irritable Bowel Syndrome with Diarrhea (IBS-D): Effects of Clostridium butyricum CBM588 Probiotic on Gastrointestinal Symptoms, Quality of Life, and Gut Microbiota in a Prospective Real-Life Interventional Study
Pierro, F. D., Ficuccilli, F., Tessieri, L., Menasci, F., Pasquale, C., Khan, A. P., Rabbani, F., Memon, N. M., Cazzaniga, M., Bertuccioli, A., et al. (2025) · Microorganisms · doi:10.3390/microorganisms13051139 · Cited by 9 · see citing works
Controlling Intestinal Infections and Digestive Disorders Using Probiotics
Kumar, S., Ahmad, M. F., Nath, P., Roy, R., Bhattacharjee, R., Shama, E., Gahatraj, I., Sehrawat, M., Dasriya, V. L., Dhillon, H. S., et al. (2023) · Journal of Medicinal Food · doi:10.1089/jmf.2023.0062 · Cited by 10 · see citing works
Psychobiotics as an Intervention in the Treatment of Irritable Bowel Syndrome: A Systematic Review
Gwioździk, W., Helisz, P., Grajek, M. K., & Krupa-Kotara, K. H. (2023) · Applied Microbiology · doi:10.3390/applmicrobiol3020032 · Cited by 8 · see citing works
“[60] A single-centre, randomised, double-blind, placebo-controlled trial of adult patients with symptomatic IBS.”
Background
Could the Microbiota Be a Predictive Factor for the Clinical Response to Probiotic Supplementation in IBS-D? A Cohort Study
Marchix, J., Quénéhervé, L., Bordron, P., Aubert, P., Durand, T., Oullier, T., Blondeau, C., Abdellah, S. A., Varannes, S. B. D., Chaffron, S., et al. (2023) · Microorganisms · doi:10.3390/microorganisms11020277 · Cited by 9 · see citing works
“The clinical results are consistent with those of previous studies evaluating the combinations of several probiotic strains, some specifically in IBS-D patients [11,31,32].”
Result
Probiotics for Irritable Bowel Syndrome: An Updated Systematic Review and Meta‐Analysis With Trial Sequential Analysis
Tang, A. S. P., Quek, J., Sulaimi, F., Sim, B., Kai, T. O. S., Soon, E. Y., Goh, C. N., Hsu, J. L. J., Lee, C. K. L., Chong, S. K. S., et al. (2026) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.70322 · Cited by 5 · see citing works
Probiotics and Prebiotics for the Treatment of Irritable Bowel Syndrome—A Narrative Review
Lopes, C. M., Monteiro, C. S. D. J., Duarte, A. P., & dos Santos, J. L. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13216337 · Cited by 6 · see citing works
“In two of these studies, there was symptomatic improvement without significant differences concerning the varying dosages used [108,118], however, in one of them, there was a more significant reduction in symptoms at the higher dose [82].”
Background
Mechanism-Oriented Therapy of Irritable Bowel Syndrome
Malagelada, J. R., & Malagelada, C. (2016) · Advances in Therapy · doi:10.1007/s12325-016-0336-3 · Cited by 7 · see citing works
Symbiotics in irritable bowel syndrome – better than probiotics alone?
Gracie, D. J., & Ford, A. C. (2015) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000199 · Cited by 7 · see citing works
Identification of the Microbiota in the Aging Process
Sarkar, A., & Pitchumoni, C. S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804024-9.00004-5 · Cited by 7 · see citing works
The Potential of Clostridium butyricum to Preserve Gut Health, and to Mitigate Non-AIDS Comorbidities in People Living with HIV
Yang, Q., Zaongo, S. D., Zhu, L., Yan, J., Yang, J., & Ouyang, J. (2024) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-024-10227-1 · Cited by 8 · see citing works
Benefits of multistrain bacteria formulations for health
Laterza, L., Gibiino, G., Scaldaferri, F., & Gasbarrini, A. (2018) · Journal of Functional Foods · doi:10.1016/j.jff.2018.05.051 · Cited by 7 · see citing works
Microbiota–host symbiosis in the pathophysiology and treatment of irritable bowel, irritable eye and irritable mind syndrome
Fehér, J., Kovács, I., Pacella, E., & Radak, Z. O. (2014) · Orvosi Hetilap · doi:10.1556/oh.2014.29987 · Cited by 4 · see citing works
Fermented food microbiome: influence on oral and gut microbiota, and human health
Kim, D., Joe, H.-I., Bae, J., Wu, G. D., Compher, C. W., & Koo, H. (2026) · Nature Reviews Microbiology · doi:10.1038/s41579-026-01333-8 · Cited by 4 · see citing works
“Multi-strain liquid probiotic formulations are commercially available, and clinical studies demonstrate their positive effects in improving symptoms and in modulating microbial composition in individuals with irritable bowel syndrome and inflammatory bowel disease 219,220 .”
Low-dose titrated amitriptyline as second-line treatment for adults with irritable bowel syndrome in primary care: the ATLANTIS RCT
Wright-Hughes, A. M., Ford, A. C., Alderson, S. L., Ow, P. L., Ridd, M. J., Foy, R., Bishop, F. L., Chaddock, M., Cook, H., Cooper, D., et al. (2024) · Health Technology Assessment · doi:10.3310/bfcr7986 · Cited by 7 · see citing works
Screening of probiotic strains to improve visceral hypersensitivity in irritable bowel syndrome by using in vitro and in vivo approaches
Torres-Maravilla, E., Carvalho, F. A., Holowacz, S., Delannoy, J., Lenoir, L., Jacouton, E., Barbut, F., Langella, P., Bermúdez‐Humarán, L. G., & Waligora‐Dupriet, A. (2024) · Beneficial Microbes · doi:10.1163/18762891-bja00006 · Cited by 5 · see citing works

Authors: Sisson, G., Ayis, S., Sherwood, R. A., & Bjarnason, I.
Affiliations: Darent Valley Hospital (GB)
King's College Hospital (GB)
Corresponding author: Sisson, G.
ORCID: Ayis, S.
Sherwood, R. A.
Bjarnason, I.
Venue: Alimentary Pharmacology & Therapeutics
Publisher: Wiley
Published: 2014-05-11
Volume: 40
Issue: 1
Pages: 51-62
ISSN: 0269-2813 (ISSN-L)
1365-2036
DOI: 10.1111/apt.12787
OpenAlex: W2080104941
Cited by: 147
References: 45
Citations by year: 2026: 10 · 2025: 7 · 2024: 17 · 2023: 18 · 2022: 13 · 2021: 12 · 2020: 8 · 2019: 10 · 2018: 20 · 2017: 6 · 2016: 11 · 2015: 10 · 2014: 5
FWCI: 10.69
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by-nc-nd
creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
doi.wiley.com/10.1002/tdm_license_1.1 (tdm)
Locations: Alimentary Pharmacology & Therapeutics (publishedVersion, cc-by-nc-nd)
PubMed (publishedVersion)
Research Portal (King's College London) (submittedVersion)
Topics: Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
Keywords: irritable bowel syndrome, probiotics, multi-strain probiotics, IBS symptom severity, IBS quality of life, gut microbiota, probiotic efficacy, placebo comparison
MeSH terms: Adult, Double-Blind Method, Female, Humans, Male, Middle Aged, Quality of Life, Severity of Illness Index, Treatment Outcome, Probiotics, Irritable Bowel Syndrome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Randomised clinical trial: a liquid multi‐strain probiotic vs. placebo in the irritable bowel syndrome – a 12 week double‐blind study

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Record

About these checks